FDC launches 2 variants of Favipiravir in India at Rs 55 per pill

Picture Supply : SOCIAL MEDIA

FDC launches 2 variants of Favipiravir in India at Rs 55 per pill

Drug agency FDC Ltd on Tuesday mentioned it has launched two variants of the COVID-19 drug Favipiravir below the model names PiFLU and Favenza. The Drug Controller Basic of India (DCGI) had earlier authorised the usage of Favipiravir, an off-patent, oral antiviral drug that has been proven to quicken scientific restoration in COVID-19 sufferers with gentle to reasonable signs, FDC mentioned in a press release.

Read Also:  Vodafone Thought shares bounce 30 % board assembly fund elevating

“Early prognosis and therapy will assist in arresting the deteriorating situation of sufferers, and we will probably be working with the federal government and healthcare fraternity to make Favenza and PiFLU obtainable throughout the nation” FDC spokesperson Mayank Tikkha mentioned.

Read Also:  Sabarimala temple to faucet on large gold reserve, TDB to method RBI for gold loans

Each the merchandise are at present obtainable throughout the nation, the corporate mentioned.

The value per pill is Rs 55 for each the variants, it added. 

Read Also:  Railways cancels tender for 44 Vande Bharat trains after Chinese language agency emerged as contender make in India piyush goyal

Shares of FDC Ltd closed at Rs 317.50 per scrip on BSE, down 1.17 per cent over earlier shut.

Newest Information on Coronavirus

Newest Enterprise Information

Struggle in opposition to Coronavirus: Full protection

Shreya Sharma

Hey this is Shreya From ShoppersVila News. I'm a content creator belongs from Ranchi, India. For more info contact me [email protected]

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button